Rare Disease

Your Partner for Development and Commercialization of Rare Disease Treatments

Home » Rare Disease

Rare diseases present unparalleled challenges for patients. At Alira Health, we help companies develop and commercialize rare disease treatments with the intense focus on the unique needs of rare disease patients that is crucial to your success. With a continuum of patient-centric solutions, we work with you to successfully develop and provide life-changing treatments to the patients.

From clinical trial patient recruitment and retention to crafting a patient-centric product strategy, our transversal team stands by you every step of the way.

Full Lifecycle of Rare Disease Services for Your Success

Regulatory

Clinical and Biometrics

Market Access

Real-world Evidence

Commercial

Regulatory

Clinical and Biometrics

Market Access

Real-world Evidence

Commercial

Tailored and Truly Patient-Centric Approach for Rare Disease Treatments

Navigating the complexities of rare disease product development requires a nuanced approach. We know how to meet healthcare system expectations and offer an unmatched continuum of patient-centric solutions to aid you in this journey.

Our multidisciplinary team boasts:

A profound understanding of patients' perspectives and their true unmet needs
Extensive connections with patient organizations and key opinion leaders
A proven track record in rare disease projects across various indications
Experience in de-risking and accelerating the path to clinical development and commercialization in both pediatric and adult indications
Membership in leading rare disease associations such as EURORDIS

Patient engagement is key to bringing new drugs and medical devices to markets and securing patient access to these therapies across all disease areas. It is particularly important in rare diseases where patients are often the most expert on their disease.

When patients can be involved in the clinical development plan and creation of the trial protocol and are encouraged to provide in-trial feedback, they are more likely to stay in the trial, understand their responsibilities, and adhere to the protocol requirements.

Annabel de Maria, Chief Patient Officer
Rare disease patient | Patient representative for the EULAR working group on autoinflammatory diseases

Latest Rare Disease Insights

The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases

We spoke with Alira Health’s Annabel de Maria, Chief Patient Officer and Ahmad Bechara, Executive Vice President Global Pharma about how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact on the outcome.

Creating Patient-Centric Clinical Trials in Rare Disease

For sponsors and CROs, patient engagement is critical. This guide explores specific opportunities for sponsors, CROs, and trial sites to develop patient-centric clinical trials for rare diseases.

Case Study: Mid-size Pharma Accelerates Early Clinical Trial Engagement Of Patients With A Rare Neurological Disease

Alira Health helped the client make the rare disease clinical study more accessible and feasible to patients through a Patient Advisory Board. The patient relationships generated helped to expand the client’s reach and involvement in clinical trials.